Augmedix (AUGX) Q2 2024 earnings summary

Executive summary

• Revenue grew 27% year-over-year to $13.7M for Q2 2024, driven by a 22% increase in average clinicians in service and a 3% rise in average annual revenue per clinician.

• Net loss widened to $8.5M from $5.0M in Q2 2023, reflecting higher operating expenses, including $1.2M in legal/professional costs related to a pending merger.

• Gross margin improved to 47.2% from 45.6% year-over-year, aided by operational efficiencies and product mix.

• The company is progressing toward a merger with Commure, Inc., expected to close in late Q3 or early Q4, with shareholders to receive $2.35 per share in cash.

• Civil unrest in Bangladesh, where 75% of employees are based, disrupted operations in July and poses ongoing risk.

Financial highlights

• Q2 2024 revenue: $13.7M, up from $10.8M in Q2 2023; six-month revenue: $27.1M, up 33% year-over-year.

• Q2 2024 net loss: $8.5M ($0.16/share) vs. $5.0M ($0.12/share) in Q2 2023; six-month net loss: $14.9M ($0.28/share) vs. $10.3M ($0.25/share) year-over-year.

• Gross margin for Q2 2024: 47.2% (Q2 2023: 45.6%); six-month gross margin: 47.2% (2023: 46.3%).

• Cash, cash equivalents, and restricted cash at June 30, 2024: $33.4M, down from $46.3M at year-end 2023.

• Operating cash outflow for six months: $12.0M; capital expenditures: $0.9M.

Outlook and guidance

• Management expects lower revenue growth rates in 2024 compared to 2023 due to slower purchasing commitments and product mix shift, but anticipates gross margin expansion as more customers adopt higher-margin AI-driven products.

• Management anticipates scaling ambient documentation solutions and leveraging AI capabilities post-merger with Commure.

• Cash balance is expected to cover working capital needs for over twelve months from the filing date.